Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous B7-H3 CAR T Cells in SCLC and EPNEC
NCT07509034Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2026
- Primary completion
- Jan 2030
- Countries
- 1
01
Overview
Phase 1, open-label trial in small cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose or Maximum Administered Dose at 28 days and Disease Control Rate up to 15 years. Started Oct 2026; status: recruiting.
02
Conditions
small cell lung cancer (SCLC)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT07509034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07509034.